Bloomberg Talks
Moderna CEO Stephane Bancel Talks Skin Cancer
Dec 14, 2023
Moderna CEO Stephane Bancel discusses joint efforts with Merck to create a skin cancer vaccine. They cover accelerated approval, improved survival rates, expansion into more cancer studies, sales performance, market share, future plans, and the company's impact in saving lives.
07:44
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Moderna is developing individualized treatments for skin cancer using customized chemical drugs based on the DNA of each patient's cancer cells, showing a 49% improvement in three-year survival for melanoma patients compared to current options.
- Moderna anticipates significant sales growth in an endemic COVID market, with an estimated $4 billion in sales in 2024, and plans to launch RSV treatment in 2024, emphasizing their strong pipeline and platform approach for drug development.
Deep dives
Moderna's Individualized Treatment for Skin Cancer
Moderna is using its technology to develop individualized treatments for skin cancer. They are creating different chemical drugs customized to the DNA of each patient's cancer cells. The data from their drug shows a 49% improvement in three-year survival for melanoma patients compared to the current best drug available. Moderna is rushing the treatment into phase three and seeking accelerated approval due to its strong safety profile. They are partnered with Merck commercially and clinically to further develop and study the treatment.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
